Navigation Links
Epizyme to Partner to Develop DOT1L Companion Diagnostic
Date:4/18/2013

CAMBRIDGE, Mass., April 18, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has signed an agreement with Abbott, a global healthcare company, to develop a molecular companion diagnostic test for use with EPZ-5676. EPZ-5676, Epizyme's most advanced clinical product candidate, is an inhibitor targeting the DOT1L histone methyltransferase (HMT) for the treatment of mixed lineage leukemia (MLL-r), an aggressive genetically defined subtype of the two most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Under the agreement, Abbott will utilize its proprietary fluorescence in situ hybridization (FISH) technology to design a test to detect MLL genetic alterations that lead to the oncogenic (cancer causing) function of DOT1L. Epizyme will use Abbott's FISH-based test to help identify eligible patients for its DOT1L inhibitor.

About mixed lineage leukemia (MLL-r)
MLL-r is an aggressive subtype of two of the most common forms of acute leukemia, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), caused by a chromosomal translocation involving the MLL gene. Based on published research, the five-year overall survival rate for adult patients with the MLL-r subtype of AML ranges from approximately 5 to 24 percent. MLL-r occurs in both an adult population and an infant/pediatric population. At this time, there are no approved therapies specifically indicated for MLL-r.

About Epizyme, Inc.
Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that we use to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). To date, Epizyme has entered into therapeutic collaborations with Celgene, Eisai and GSK that have provided it with approximately $120 million in non-equity funding through December 31, 2012. 

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme to Present at Upcoming Conferences in February
2. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
3. Tria Beauty, Inc. and Ulta Announce New Retail Partnership
4. Richard Atkin to Join MedTech Nordic Investing & Partnering 2013
5. RoundTable Healthcare Partners and Argon Medical Devices Complete Acquisition of Angiotech Pharmaceuticals Interventional Products Business
6. Profil Institute and Mercodia Announce Partnership Offering Insulin and Metabolism ELISA Assays to Enhance Diabetes and Obesity Clinical Trials
7. Core Informatics and OpenEye Scientific Software Forge Partnership
8. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
9. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
10. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today
11. GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... 2017 Kohll,s Pharmacy & Homecare is the first distributor ... States . The Raizer is a simple battery operated ... to an almost-standing position within a few minutes. ... assistant and does not require any extra effort besides ... child can operate it, and lightweight and portable ...
(Date:5/30/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the Goldman ... June 13, 2017, in Rancho Palos Verdes, California ... executive officer, is scheduled to present at 3:20 p.m. Pacific ... at http://ir.hill-rom.com/events.cfm . A recorded replay will be available ... 13, 2017. About ...
(Date:5/24/2017)... HAMPTON, Va. , May 24, 2017 /PRNewswire/ ... ivWatch Original Equipment Manufacturer (OEM) Board to enable ... technology with patient monitoring systems, infusion pumps and ... products, OEMs will be able to help health ... care and reduced risks related to IV therapy. ...
Breaking Medicine Technology:
(Date:6/28/2017)... FRANCISCO AND TEL AVIV (PRWEB) , ... June ... ... 3D-imaging sensor company whose technology makes it possible to see through objects, has ... challenging makers to create consumer apps with its fully programmable, Raspberry Pi-enabled 3D ...
(Date:6/28/2017)... ... 2017 , ... Drs. Steven Crandall, Karen Johnson and Kathy Lopez are now ... St. Clair, PA, without a referral. The doctors address jaw pain and ... joint and facial muscles that support it. , Jaw pain can be debilitating, ...
(Date:6/28/2017)... ... ... B. Sosin, a founding partner at the law firm Sosin, Arnold & Schoenbeck, ... the Illinois State Bar Association , in accordance with the organization’s rules of succession. ... a state-wide election and served in that capacity for the past year prior to his ...
(Date:6/28/2017)... ... 28, 2017 , ... Schneider Insurance and Financial, a Yellowstone ... southern Montana, is announcing a focused charity effort to gather regional support for ... by Zoo Montana provide students with current knowledge on the characteristics and behaviors ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 percent of ... released today by the American Society for Dermatologic Surgery (ASDS). , ... of consumers considering a cosmetic medical procedure has doubled since 2013. , “Cosmetic ...
Breaking Medicine News(10 mins):